Enovis (NYSE:ENOV – Get Free Report) and electroCore (NASDAQ:ECOR – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, earnings, analyst recommendations, valuation and risk.
Profitability
This table compares Enovis and electroCore’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Enovis | -47.96% | 12.03% | 4.91% |
| electroCore | -39.96% | N/A | -81.35% |
Analyst Recommendations
This is a summary of recent recommendations for Enovis and electroCore, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Enovis | 1 | 1 | 10 | 0 | 2.75 |
| electroCore | 1 | 1 | 1 | 0 | 2.00 |
Earnings and Valuation
This table compares Enovis and electroCore”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Enovis | $2.25 billion | 0.47 | -$1.18 billion | ($19.26) | -0.95 |
| electroCore | $32.03 million | 2.61 | -$13.97 million | ($1.66) | -5.59 |
electroCore has lower revenue, but higher earnings than Enovis. electroCore is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Enovis has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500. Comparatively, electroCore has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.
Institutional and Insider Ownership
98.5% of Enovis shares are held by institutional investors. Comparatively, 26.7% of electroCore shares are held by institutional investors. 2.9% of Enovis shares are held by insiders. Comparatively, 7.8% of electroCore shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Enovis beats electroCore on 9 of the 14 factors compared between the two stocks.
About Enovis
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.
About electroCore
electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general health and wellbeing; and TAC-STIM for human performance. In addition, the company offers gammacore Sapphire, a portable, reusable, rechargeable, and reloadable prescription medical device for various primary headache conditions. electroCore, Inc. was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
